Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
100.00%
Operating Margin
80.43%
Net Margin
86.84%
Efficiency Metrics
Revenue per Expense Ratio
5.11
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.8500000000
Balance Sheet Analysis
Current Ratio
3.61
Cash Ratio
0.03
Working Capital
$7.79M
Debt to Equity
0.68
Debt to Assets
40.27%
Equity Ratio
59.41%
Cash Flow Analysis
Operating Cash Flow Ratio
57.31%
Free Cash Flow Ratio
57.31%
CapEx to Revenue
0.00%
Dividends Paid
$24.24M
Stock Buybacks
No buybacks
Total Shareholder Returns
$24.24M
Cash Position Change
2,395,691,000.0%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
149.70%
Net Income
141.68%
EPS
141.67%
Operating Income
138.60%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
174.74%
Operating Cash Flow
-51.53%
Free Cash Flow
-51.53%
Balance Sheet Health
Assets
1.31%
Debt
18,174.97%
Book Value per Share
2.59%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-17.87%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
1,463.46%
5Y Revenue/Share
56.02%
3Y Dividend/Share
-20.56%
5Y Dividend/Share
-23.49%